Novo Nordisk, obesity
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...
STORY: Shares of Novo Nordisk tumbled 10% Monday morning after the drugmaker revealed weaker-than-expected data about its latest obesity drug candidate, CagriSema. Investors were hoping a ...
Novo Nordisk shares fell ... CagriSema is a two-drug combination that mixes its blockbuster Semaglutide drug found in Ozempic and Wegovy, with a experimental drug cagrilintide.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results